{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-042695","form_type":"8-K","ticker":"ANVS","cik":"0001477845","company_name":"Annovis Bio, Inc.","filed_at":"2024-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.590440+00:00","generated_at":"2026-06-04T02:48:55.548055+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Annovis Bio FY 2023 net loss $56.2M; cash $5.8M; PD Phase III completed, AD top-line data expected April","bullets":["Net loss Q4 2023 $22.2M vs $7.7M YoY; FY net loss $56.2M vs $25.3M.","Cash and equivalents $5.8M as of Dec 31, 2023, down from $28.4M.","R&D expenses $38.8M for FY 2023, up from $16.5M, driven by AD and PD trial costs.","PD Phase III completed with 471 patients; AD Phase II/III fully enrolled (353 patients); top-line efficacy data expected in April 2024.","Appointed Andrew Walsh as VP Finance in December 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-042695","json":"https://secwatch.observer/filing/0001104659-24-042695.json","markdown":"https://secwatch.observer/filing/0001104659-24-042695.md","text":"https://secwatch.observer/filing/0001104659-24-042695.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924042695/0001104659-24-042695-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924042695/tm2410669d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T02:48:55.548055+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4e126ef48a20bb34312034d68c9f98822f6e70da","claim":"Annovis Bio, Inc. reported fourth quarter and full year 2023 results: net income $22.2 million.","evidence_excerpt":"today provided a summary of corporate updates and reported fourth quarter and full year 2023 financial results.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924042695/0001104659-24-042695-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year 2023"},{"label":"Net income","value":"$22.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}